Company Overview

Corporate Information

Business Model (Strengths and Competitive Advantages)

Value Creation Model Driven by Expertise in the Hormone Field

Under its Purpose, “Tomorrow and Beyond, Healthy for All Life,” ASKA Pharmaceutical Holdings Group creates value by leveraging the expertise in the hormone field and strengths in specialty areas that it has cultivated over more than 100 years. Building on its core competencies, namely highly skilled people and organizational capabilities, trusted relationships with stakeholders, and a strong presence in specialty fields, the Group is advancing five growth-driving businesses: Domestic Prescription Pharmaceuticals, Drug Discovery, Global Business, Animal Health, and Diagnostics & Around-the-Pill Solutions.
Drawing on the expertise and customer base developed through its Domestic Prescription Pharmaceuticals business, the Group is expanding its business portfolio through the creation of new value in drug discovery, global expansion centered on Asia, applications in the animal health field, and total healthcare solutions encompassing diagnostics, testing, and prognostic care. Through synergies among these businesses, the Group seeks to address social challenges and achieve sustainable growth, with the goal of becoming a globally recognized specialty healthcare company creating value worldwide by 2035.

Healthcare for women

• A leading company in the Ob/Gyn field
• Top sales in the Ob/Gyn field (In-house estimate for FY2025)

Endocrine hormones

• Endocrine hormone R&D Over 100 years
• A leading company in the thyroid field
• 95% share of domestic market
  
  

Global

• Expanding business operations across Southeast Asia, with a focus on Vietnam and the Philippines
• Strengthening supply capabilities through the utilization of Hataphar’s new manufacturing facility
• Providing products tailored to local market needs

Animal Health

• Large market presence in the livestock field thanks to lineup of mainstay breeding hormone preparations
• Products addressing untapped needs in the companion animal market
• Contribution to greater uptake of low-protein feed through full lineup of feed-use amino acids

Microdetermination (non-invasive testing)

• High-sensitivity measurement using liquid chromatography-tandem mass spectrometry (LC-MS/MS)
• Multi-item simultaneous steroid hormone measurement
• Ultra-high-sensitive estrogen measurement
• Measurement of thyroid-related substances
• Measurements using non-invasive samples

Consolidated Sales

Core Information

(As of June 24, 2026)

*Number of employees is the number of full-time employees who actually work as of March 31, 2026. Figures in parentheses represent the average number of temporary employees during the year and are not included in the number of full-time employees.